MEN2501

· Stemline Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MEN2501, covering 2025-11-10 to 2025-11-10. Get the full timeline:

Most recent: Clinical Trial Update: A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer [Phase 1]